New cause identified for necrotic enteritis in chicken

Researchers from Monash University and CSIRO Livestock Industries have demonstrated for the first time that alpha-toxin protein, long thought to be required for necrotic enteritis to develop, is not the main cause of the chicken disease. The study, published February 8 in the open-access journal PLoS Pathogens, provides insight into one of the world’s most common and financially crippling poultry diseases.

“It’s caused by Clostridium perfringens, a bacterium found in soil, litter, dust and in small quantities in the intestines of healthy chickens,” said co-author Anthony Keyburn, “The bacterium only causes disease when it proliferates to high numbers, producing extracellular toxins that attack the bird’s intestines, causing lesions.” .

Poultry producers use antibiotics to treat and prevent the disease, which, when triggered, can cause mortality rates of up to 50 per cent. Necrotic enteritis costs the world’s poultry industries an estimated US$2 billion every year.

The disease was first described in 1961 and alpha-toxin was implicated as the major causative factor, although definitive proof has never been reported. As a result, for the last 30 years all vaccine development work has been based on the assumption that alpha-toxin was the key.

Mr Keyburn said the research team began to question the involvement of alpha-toxin when a survey showed that local disease-causing bacterial strains produced low levels of this toxin.

“We tested the importance of alpha-toxin by genetically altering the bacterium so it no longer produced any of the protein,” he said. “Despite the toxin’s absence, our bacterial isolates still caused disease in chickens. This demonstrates that the development of necrotic enteritis in chickens is not dependent on C. perfringens producing a functional alpha-toxin.”

This finding led the team to expand their search for the real cause of necrotic enteritis, finding a novel toxin – NetB – that is involved in the disease-causing potential of a high proportion of virulent C. perfringens strains.

The authors are now investigating NetB and other proteins produced by C. perfringens, with the aim of developing effective vaccines against the disease.

“Around the world, poultry producers are waiting for vaccines against necrotic enteritis,” said co-author Rob Moore. “Thanks to Anthony’s discoveries, scientists should now be able to develop the vaccines within a couple of years.”

Source: Public Library of Science

Related stories:

Inhibiting cholesterol-associated protein reduces high-risk blockages in arteries
Using the drug darapladib, researchers at the University of Pennsylvania School of Medicine and colleagues have inhibited a cholesterol-and immune system-associated protein, thereby reducing the development of heart-disease plaques that may cause death, heart attacks, and strokes in a pig model of atherosclerosis and diabetes. The study appeared online this week in Nature Medicine.
How cells die determines whether immune system mounts response
Every moment we live, cells in our bodies are dying. One type of cell death activates an immune response while another type doesn't. Now researchers at Washington University School of Medicine in St. Louis and St. Jude's Children's Research Hospital in Memphis have figured out how some dying cells signal the immune system. They say the finding eventually could have important implications in the treatment of autoimmune diseases and cancer.
Stopping unwanted cell death: Implications for drug discovery
Research published in Nature Chemical Biology reveals that three specific inhibitors of a cell death pathway, termed necroptosis, all target and inhibit RIP1 kinase, a protein that can direct cells into necrosis. Induced by trauma such as a heart attack or stroke, this form of necrotic death can result in tissue damage contributing to death or long-term disability. The findings present a novel avenue for drug development.
Investigational drug tested for preventing muscle fiber death in muscular dystrophy
An investigational antiviral drug currently undergoing human trials in Europe for treating Hepatitis C infections may have potential to reduce muscle cell damage in Duchenne and other forms of muscular dystrophy (MD). A research team led by Cincinnati Children’s Hospital Medical Center reported their results using three different mouse models of MD in a letter posted online March 16 by the journal Nature Medicine.
Pathway to cell death redefined in landmark study
A new study led by investigators from the University of Pittsburgh School of Medicine demonstrates that the process of necrosis, long thought to be a chaotic, irreversible pathway to cell death, may actually be triggered as part of a regulated response to stress by a powerful protein, SRP-6, that can potentially halt necrosis in its path. Further, the research team realized that this protein might be harnessed to direct some cells -- those in cancerous tumors, for instance -- to die, while saving others, such as degenerating neural cells responsible for Alzheimer’s and Parkinson’s diseases. The work appears on the Sept. 21 cover of the journal Cell.
How the plant immune system can drive the formation of new species
Plant geneticists know that not all plants from the same species can be successfully bred. Apparently, there are reproductive barriers that not only prevent the exchange of genes between well-established species (which goes to the very definition of a species), but also between varieties of one and the same species. How these barriers arise is of central importance if one wants to understand the origin of biodiversity.

News discussion:

General Science news